JP2017525737A5 - - Google Patents

Download PDF

Info

Publication number
JP2017525737A5
JP2017525737A5 JP2017512046A JP2017512046A JP2017525737A5 JP 2017525737 A5 JP2017525737 A5 JP 2017525737A5 JP 2017512046 A JP2017512046 A JP 2017512046A JP 2017512046 A JP2017512046 A JP 2017512046A JP 2017525737 A5 JP2017525737 A5 JP 2017525737A5
Authority
JP
Japan
Prior art keywords
group
alkyl
substituted
cycloalkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017512046A
Other languages
English (en)
Japanese (ja)
Other versions
JP6506390B2 (ja
JP2017525737A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2015/088799 external-priority patent/WO2016034108A1/zh
Publication of JP2017525737A publication Critical patent/JP2017525737A/ja
Publication of JP2017525737A5 publication Critical patent/JP2017525737A5/ja
Application granted granted Critical
Publication of JP6506390B2 publication Critical patent/JP6506390B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017512046A 2014-09-02 2015-09-01 キノリノン系化合物及びその薬物への使用 Active JP6506390B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410442574 2014-09-02
CN201410442574.4 2014-09-02
PCT/CN2015/088799 WO2016034108A1 (zh) 2014-09-02 2015-09-01 喹啉酮类化合物及其应用

Publications (3)

Publication Number Publication Date
JP2017525737A JP2017525737A (ja) 2017-09-07
JP2017525737A5 true JP2017525737A5 (enExample) 2018-06-14
JP6506390B2 JP6506390B2 (ja) 2019-04-24

Family

ID=55417512

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512046A Active JP6506390B2 (ja) 2014-09-02 2015-09-01 キノリノン系化合物及びその薬物への使用

Country Status (8)

Country Link
US (1) US10065928B2 (enExample)
EP (1) EP3190104B1 (enExample)
JP (1) JP6506390B2 (enExample)
CN (1) CN105384687B (enExample)
AU (1) AU2015311333B2 (enExample)
CA (1) CA2959688C (enExample)
ES (1) ES2898476T3 (enExample)
WO (1) WO2016034108A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106146414A (zh) * 2016-07-07 2016-11-23 浙江大学 喹唑啉二酮类衍生物及其制备方法和用途
CN108069952B (zh) * 2016-11-08 2022-09-27 广东东阳光药业有限公司 喹啉酮类化合物及其在药物中应用
CN108069957B (zh) * 2016-11-09 2022-11-04 广东东阳光药业有限公司 脯氨酰羟化酶抑制剂及其用途
CN108285460A (zh) * 2017-01-09 2018-07-17 南京圣和药业股份有限公司 一种egfr激酶抑制剂的药用盐及其制备方法与用途
JP6999469B2 (ja) * 2018-03-28 2022-01-18 東京応化工業株式会社 水素バリア剤、水素バリア膜形成用組成物、水素バリア膜、水素バリア膜の製造方法、及び電子素子
CN111269176A (zh) * 2019-11-28 2020-06-12 南北兄弟药业投资有限公司 喹啉酮类化合物的晶型
CN111269177B (zh) * 2019-11-28 2023-05-09 广东东阳光药业有限公司 喹啉酮类化合物的晶型
ES3061349T3 (en) 2019-11-28 2026-04-01 Sunshine Lake Pharma Co Ltd Crystal form of 2-(4-hydroxy-1-methyl-2-oxo-7-phenoxy-1,2-dihydroquinoline-3-carboxamido)acetic acid
CN111269178A (zh) * 2019-11-28 2020-06-12 南北兄弟药业投资有限公司 喹啉酮类化合物的晶型
WO2022184159A1 (zh) * 2021-03-05 2022-09-09 广东东阳光药业有限公司 喹啉酮类化合物的晶型及其用途
CN115010664A (zh) * 2021-03-05 2022-09-06 广东东阳光药业有限公司 喹啉酮类化合物的晶型及其用途
CN115010663A (zh) * 2021-03-05 2022-09-06 广东东阳光药业有限公司 喹啉酮类化合物的晶型及其用途
CN114989085B (zh) * 2022-05-23 2023-11-24 安徽医科大学 一种芳基内酰胺环类化合物、药物组合物及其应用
CN117159549B (zh) * 2023-10-11 2025-02-14 中国药科大学 一种酯类化合物的应用
CN121405623A (zh) * 2024-07-24 2026-01-27 合肥医工医药股份有限公司 喹啉衍生物及其制备方法和用途

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100932169B1 (ko) * 2003-06-06 2009-12-16 피브로겐, 인크. 질소-함유 헤테로아릴 화합물 및 내인성 적혈구생성소의증가에서의 그들의 사용
JPWO2006088246A1 (ja) * 2005-02-18 2008-07-10 武田薬品工業株式会社 Gpr34受容体機能調節剤
CN101166745A (zh) 2005-03-02 2008-04-23 菲布罗根有限公司 噻吩并吡啶化合物和其使用方法
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
AU2006326662B2 (en) * 2005-12-09 2011-07-28 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
WO2007090068A2 (en) 2006-01-27 2007-08-09 Fibrogen, Inc. Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
AR059733A1 (es) 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
EP2016078B1 (en) 2006-04-04 2016-06-15 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as hif modulators
WO2007136990A2 (en) 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
NZ601730A (en) 2006-06-26 2014-04-30 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
EP2111399A2 (en) 2006-12-18 2009-10-28 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
ES2393326T3 (es) 2006-12-18 2012-12-20 Amgen, Inc Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
AU2008241503A1 (en) * 2007-04-18 2008-10-30 Merck Sharp & Dohme Corp. Novel 1,8-naphthyridine compounds
ES2446418T3 (es) 2007-04-18 2014-03-07 Amgen, Inc Derivados de indanona que inhiben la prolil hidroxilasa
EP2142509B1 (en) 2007-04-18 2013-12-04 Amgen, Inc Quinolones and azaquinolones that inhibit prolyl hydroxylase
US8030346B2 (en) 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
CA2696725A1 (en) 2007-08-10 2009-03-26 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039322A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009073497A2 (en) 2007-11-30 2009-06-11 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
US20100305154A1 (en) 2007-11-30 2010-12-02 Glaxosmithkline Llc Prolyl Hydroxylase Inhibitors
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
EP2240178A4 (en) 2007-12-19 2011-10-26 Glaxosmithkline Llc PROLYLHYDROXYLASEHEMMER
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
CN101951775A (zh) 2008-02-25 2011-01-19 默沙东公司 四氢噻吩并吡啶
CA2716798A1 (en) 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Tetrahydrofuropyridones
CA2714111A1 (en) 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Tetrahydro-1h-pyrrolo fused pyridones
US8759345B2 (en) 2008-04-28 2014-06-24 Janssen Pharmaceutica Nv Benzoimidazoles as prolyl hydroxylase inhibitors
WO2009134850A1 (en) 2008-04-30 2009-11-05 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009134847A1 (en) 2008-04-30 2009-11-05 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JP2011525924A (ja) 2008-06-25 2011-09-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
US8217043B2 (en) 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
WO2010022307A2 (en) 2008-08-21 2010-02-25 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JP2012500850A (ja) 2008-08-25 2012-01-12 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
CN102272117B (zh) 2008-11-14 2015-06-17 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
WO2010093727A1 (en) 2009-02-10 2010-08-19 Janssen Pharmaceutica Nv Quinazolinones as prolyl hydroxylase inhibitors
CN102164905B (zh) 2009-07-15 2014-04-30 北京贝美拓新药研发有限公司 作为体内缺氧模拟剂的化合物,组合物,及其应用
PT2455381E (pt) 2009-07-17 2014-06-24 Japan Tobacco Inc Composto de triazolopiridina e sua acção como inibidor da prolil-hidroxilase e indutor da produção de eritropoietina
WO2011048611A1 (en) 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives
TWI500623B (zh) 2009-10-13 2015-09-21 Torrent Pharmaceuticals Ltd 新穎稠合噻唑及噁唑嘧啶酮
WO2011056725A1 (en) 2009-11-05 2011-05-12 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
US8541430B2 (en) 2009-11-27 2013-09-24 Torrent Pharmaceuticals Limited Fused thiazolo and oxazolo pyrimidinones
US8796263B2 (en) 2010-08-13 2014-08-05 Janssen Pharmaceutica Nv 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors
CN103608346B (zh) 2011-02-02 2016-06-15 菲布罗根有限公司 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物
NO2686520T3 (enExample) 2011-06-06 2018-03-17
EP3251671A1 (en) 2011-06-06 2017-12-06 Akebia Therapeutics Inc. Compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
JP2014523917A (ja) 2011-07-29 2014-09-18 ベイジン ベータ ファーマシューティカルズ カンパニー, リミテッド 低酸素模倣剤としての化合物の安定な多形体、およびその使用
SG11201405574UA (en) 2012-03-09 2014-10-30 Fibrogen Inc 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
US9340511B2 (en) 2012-07-16 2016-05-17 Fibrogen, Inc. Process for making isoquinoline compounds
AU2013297601B2 (en) 2012-07-30 2017-02-16 Taisho Pharmaceutical Co., Ltd. Partially saturated nitrogen-containing heterocyclic compound
US20150239889A1 (en) 2012-08-23 2015-08-27 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine compound
NZ708605A (en) * 2012-12-24 2016-07-29 Cadila Healthcare Ltd Novel quinolone derivatives
WO2014116849A1 (en) 2013-01-24 2014-07-31 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid

Similar Documents

Publication Publication Date Title
JP2014511891A5 (enExample)
JP2019524883A5 (enExample)
JP2017523225A5 (enExample)
JP2010532387A5 (enExample)
JP2017527561A5 (enExample)
JP2018537413A5 (ja) 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物
JP2017531619A5 (enExample)
JP2016540742A5 (enExample)
JP2015522650A5 (enExample)
JP2015537020A5 (enExample)
JP2018514544A5 (enExample)
JP2014507455A5 (enExample)
JP2016505512A5 (enExample)
AR092045A1 (es) Combinaciones farmaceuticas
JP2019510034A5 (enExample)
JP2015524472A5 (enExample)
JP2015504081A5 (enExample)
JP2013542261A5 (enExample)
JP2016531126A5 (enExample)
JP2016507581A5 (enExample)
RU2012158142A (ru) Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
JP2019531279A5 (enExample)
RU2015146957A (ru) Производные доластатина 10 и ауристатинов
JP2017516796A5 (enExample)
JP2018528229A5 (enExample)